<DOC>
	<DOCNO>NCT02778477</DOCNO>
	<brief_summary>The current study first clinical trial propose PF-06423264 . It design evaluate safety , tolerability , pharmacokinetics ( PK ) follow administration multiple ascend dos PF-06423264 healthy adult subject without oily skin .</brief_summary>
	<brief_title>Topical Multiple Ascending Dose Study PF-06423264</brief_title>
	<detailed_description />
	<criteria>Healthy male female nonchildbearing potential ; Body Mass Index 17.535.5 kg/m2 ; Body weight &gt; 50 kg ; Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergises , exclude untreated , asymptomatic , seasonal allergy time dose )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>